MUR-2425
Memory loss in mild to moderate dementia (Alzheimer's, Parkinson's, Lewy body, Huntington's, etc.)
Pre-clinicalActive
Key Facts
Indication
Memory loss in mild to moderate dementia (Alzheimer's, Parkinson's, Lewy body, Huntington's, etc.)
Phase
Pre-clinical
Status
Active
Company
About Myriel
Myriel is a preclinical-stage biotech developing MUR-2425, a brain-penetrant inhibitor of caspase-2 designed to block the formation of the neurotoxic tau fragment Δtau314. Founded on foundational academic research by CEO Dr. Karen Hsiao Ashe, the company has demonstrated rapid reversal of memory loss in mouse models within 30 minutes. Myriel is advancing its lead candidate toward clinical trials with the goal of creating a once-daily treatment for mild to moderate dementia across multiple neurodegenerative indications, including Alzheimer's, Parkinson's, and Huntington's diseases.
View full company profile